Early Cancer Cells Detection with Circulating Tumour Cells (CTC) Test

Health Blog
Early Cancer Cells Detection with Circulating Tumour Cells (CTC) Test

Early Cancer Cells Detection with Circulating Tumour Cells (CTC) Test

Published On

Thursday 16th January 2025

NIIM Research

The National Institute of Integrative Medicine (NIIM) offers Circulating Tumour Cells (CTC) screening as part of an ongoing clinical trial.

A simple blood test can potentially alert you to the presence of circulating cancer cells, rare cells and viral reactivation. Our tool has been developed to screen for CTC’s to assist in early diagnosis of potential malignancy.

CTCs are well-established cancer biomarkers, referenced in 26,000 peer-reviewed articles, which can potentially assist with early cancer detection and assessment of treatment effectiveness. The CTC blood test is a one-point-in-time screening test.

At NIIM, we utilize the ISET-CTC test, a cytology-based (microscopy) method recognised for its detection sensitivity.

Unlike many traditional screening tools , according to the published data*, the CTC screen has the potential to detect twelve different types of cancer including prostate and breast. *rarecells.com/technology.

For men

the improved prostate cancer screening test combines the CTC test with the PSA marker (marker=antigen=specific protein on the surface of the cancer cell) which has higher accuracy than the PSA blood test.

While the traditional PSA blood test has an accuracy rate of just 15-25%, NIIM’s combined approach achieves an impressive 97-99% accuracy, significantly improving early detection rates and reducing the risks of false positives or missed diagnoses.

For Men

For women

the combination of CTC test and a breast marker (Mammaglobin) provides a high sensitivity and specificity, with an overall accuracy of approximately 80%.